Abstract: The present disclosure provides alfalfa plants exhibiting broad spectrum resistance to Race 1, Race 2, and Race 5 anthracnose. Such plants may comprise novel introgressed genomic regions associated with disease resistance from Race 1, Race 2, and Race 5 anthracnose. In certain aspects, compositions, including novel polymorphic markers and methods for producing, breeding, identifying, and selecting plants or germplasm with a disease resistance phenotype are provided. Also provided are alfalfa varieties designated as C0416C4164 and H0415C4114. Provided by the invention are the seeds, plants and derivatives of alfalfa varieties C0416C4164 and H0415C4114. Also provided by the invention are tissue cultures of alfalfa varieties C0416C4164 and H0415C4114, and the plants regenerated therefrom. Still further provided by the invention are methods for producing alfalfa plants by crossing alfalfa variety C0416C4164 or H0415C4114 with itself or another alfalfa variety and plants produced by such methods.

Abstract: Devices, systems, and methods are provided for adherence monitoring and patient interaction. In general, the devices, systems, and methods can facilitate a patient's adherence to a medication schedule and can facilitate monitoring and tracking of the patient's adherence to the medication schedule. In one embodiment, a medical accessory such as a cap is provided that can be configured to attach to existing medication dispensers, such as asthma inhalers, or to be integrated into a custom-made medication dispenser. The accessory can be configured to provide a notification to the patient when medication is due. The accessory can be configured to detect usage of the dispenser. The accessory can be configured to provide data regarding dispensing of the medication to an external device. The data can be analyzed and provided for visualization on a user interface.

Abstract: The present invention relates to engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them.

Abstract: The present disclosure relates to the application of a shielded and homing bispecific antibody as an effective and tissue specific treatment of cancers such as breast, lung, gastric cancers, and other HER2 over-expressed cancers. The homing domain increases the local concentration of the bispecific antibody in the tumor microenvironment, and the shielding employs masking domains that are fused via protease-cleavable linkers to the Fab domains targeting a human epidermal growth factor receptor 2 family protein and Fab domains targeting an angiogenic vascular endothelial growth factor pathway associated target. The unmasking of the shielded bispecific antibody occurs predominantly by proteases and enzymes in the tumor microenvironment. The application of such bispecific antibody minimizes systemic toxicity and expands the therapeutic index.

Abstract: The present disclosure relates to a shielded biologic with a masking domain, e.g., based on Insulin-like Growth Factor 2 (IGF2), fused to the Fab domain of an antibody via protease-cleavable linker to mask the antigen binding capability of the antibody, and to the use of said shielded biologic for effective and site-specific disease treatment while reducing systematic toxicity.

Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.

Abstract: The present invention relates to engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations and methods of making and using them.

Abstract: FN3 domains that specifically bind Fc?RII, their conjugates and antibody fusions, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them.

Abstract: Novel rodent bispecific heterodimeric proteins, such as rodent bispecific antibodies, in vitro method for producing such, and uses thereof.

Abstract: The present invention relates to engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them.

Abstract: The present invention relates to engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions.

Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.

Abstract: The present invention relates to bispecific anti-TNF-?/IL-17A antibodies and anti-TNF-? antibodies, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: FN3 domains that specifically bind Fc?RII, their conjugates and antibody fusions, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them.

Abstract: The present invention relates to engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations and methods of making and using them.

Abstract: The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of a Staphylococcus infection, including methicillin-resistant Staphylococcus aureus.

Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.

Abstract: The present invention relates to engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them.

Abstract: The present invention relates to engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions.

Abstract: Novel rodent bispecific heterodimeric proteins, such as rodent bispecific antibodies, in vitro method for producing such, and uses thereof.